• FOXM1–Estrogen Receptor Networks in Female Lung Adenocarcino

  2026-06-08

  This study establishes a mechanistic link between the transcription factor FOXM1, estrogen receptor signaling, and non-coding RNA networks in female lung adenocarcinoma (LUAD). By integrating large-scale transcriptomics and functional validation, the research identifies a novel ceRNA regulatory axis with implications for prognosis and immunotherapy responsiveness in LUAD.

• MAZ-BCKDK-G6PD Axis Drives Metabolic Reprogramming in TNBC

  2026-06-08

  This study uncovers a metabolic regulatory pathway in triple-negative breast cancer (TNBC), showing that MAZ-driven BCKDK upregulation stabilizes G6PD, thereby promoting glucose metabolism and tumor growth. These insights highlight the MAZ/BCKDK/G6PD axis as a promising therapeutic target and provide mechanistic clarity for metabolic interventions in aggressive breast cancers.

• Differential Mechanisms of Chuanxiong Cortex and Pith in CHD

  2026-06-07

  This study leverages SPME-GC×GC-MS and network pharmacology to dissect the unique bioactive profiles of Ligusticum chuanxiong rhizome cortex and pith in coronary heart disease (CHD) models. The findings highlight distinct volatile compound distributions and molecular targets, with Fenipentol (1-Phenyl-1-pentanol) emerging as a key cortex-derived modulator—offering new insights for targeted cardiovascular and gastrointestinal research.

• Native Protein Gel Electrophoresis: Precision and Innovation

  2026-06-06

  Explore how the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit enables high-resolution native protein gel electrophoresis, preserving protein activity and structure for advanced biochemical research. Discover unique scientific insights and practical guidance that go beyond standard protocols.

• Vorinostat (SAHA): Advancing Translational Oncology via Epig

  2026-06-05

  This article delivers a mechanistic and strategic blueprint for translational researchers leveraging Vorinostat (SAHA) in oncology. Integrating evidence from in vitro evaluations, apoptosis metrics, and real-world assay challenges, it advances the discussion beyond standard product summaries—focusing on actionable guidance for experimental design, protocol optimization, and the translational bridge to clinical impact.

• Gut-Brain Cholinergic Pathways in B. fragilis Antiseizure Ef

  2026-06-05

  Jia et al. reveal a mechanistic link between gut microbiota and seizure suppression, demonstrating that Bacteroides fragilis activates gut-brain cholinergic signaling to mediate antiseizure effects. Their translational approach integrates animal models with clinical validation, offering new perspectives for microbiota-targeted epilepsy therapies.

• Bufalin-CRISPR Nanomedicine Induces Pyroptosis for CRC Immun

  2026-06-04

  A recent study introduces a calcium lactate nanoparticle system co-delivering bufalin and CRISPR/Cas9 to target colorectal cancer. This approach synergistically induces pyroptosis and macrophage M1 polarization, enhancing local and systemic antitumor immunity and offering a new strategy against therapy resistance.

• Nilotinib (AMN-107): Precision Solutions for Kinase Assays

  2026-06-04

  This article guides biomedical researchers through common challenges in kinase pathway assays and immunomodulation studies, demonstrating how Nilotinib (AMN-107, SKU A8232) delivers reproducible, quantitative results. Scenario-driven Q&A blocks offer evidence-backed insights and practical workflow recommendations for cell viability, proliferation, and cytotoxicity analyses.

• Synergistic Effects of SGI-1027 and Everolimus in Renal Canc

  2026-06-03

  This study uncovers the novel cytotoxic activity of SGI-1027, a DNA methyltransferase inhibitor, in inducing methuosis and enhancing apoptosis and pyroptosis in renal cancer cells. The combination of SGI-1027 with everolimus demonstrates potent anti-tumor effects and offers a promising strategy for overcoming drug resistance in advanced renal cell carcinoma.

• GW 4869 Hydrochloride Hydrate: Exosome Inhibition in Lupus N

  2026-06-03

  GW 4869 hydrochloride hydrate emerges as the gold standard for selectively inhibiting exosome biogenesis, enabling precise dissection of intercellular signaling in autoimmune kidney disease. This article distills protocol enhancements, troubleshooting insights, and cutting-edge applications anchored in lupus nephritis models—bridging bench research with advanced experimental workflows.

• Differential Shh, Fgf10, and Fgfr2 Expression in Penile Deve

  2026-06-02

  This study reveals species-specific mechanisms underlying penile urethral and prepuce formation by comparing guinea pigs and mice. By mapping differential expression patterns of Shh, Fgf10, and Fgfr2, the authors clarify why guinea pigs and humans form a fully opened urethral groove, advancing developmental biology and providing models for translational research.

• Applied Workflows for (S)-1-(3-fluoro-4-(trifluoromethoxy)ph

  2026-06-02

  Unlock advanced control over osteoclastogenesis and redox balance with (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186). This high-purity, fluorinated phenyl urea compound from APExBIO enables robust, reproducible inhibition of soluble epoxide hydrolase, empowering bone metabolism, signaling pathway, and enzyme inhibition studies with unmatched solubility and workflow flexibility.

• Catalpol (N1352): Technical Guidance for Disease Model Resea

  2026-06-01

  Catalpol (N1352) offers well-characterized support for neuroprotection research, osteoporosis animal models, and preclinical studies of ischemic stroke and liver fibrosis. This guide provides actionable protocol parameters and workflow considerations for disease modeling applications. Catalpol should not be used outside validated experimental systems or with unsupported mechanistic claims.

• Nilotinib (AMN-107): Enabling Translational Immuno-Oncology

  2026-06-01

  Nilotinib (AMN-107) is widely recognized as a selective tyrosine kinase inhibitor central to chronic myeloid leukemia and gastrointestinal stromal tumor research. Recent findings, however, reveal a groundbreaking immunomodulatory mechanism that positions nilotinib at the forefront of translational strategies to overcome immune checkpoint inhibitor resistance. This article offers a mechanistic deep dive, strategic guidance for experimental design, and actionable best practices for researchers seeking to unlock the next generation of targeted and immune-based cancer therapies.

• Ceapin-A7: Scenario-Driven Guidance for Reliable ER Stress A

  2026-05-31

  This article provides laboratory-tested, scenario-driven strategies for deploying Ceapin-A7 (SKU BA3709) as a selective ER stress blocker in cell-based assays. It addresses real-world challenges in assay reproducibility, pathway specificity, and vendor selection, supporting your workflow with quantitative evidence and accessible protocols. The practical value of Ceapin-A7 is grounded in both peer-reviewed literature and validated supplier performance.

16319 records 5/1088 page Previous Next 12345 下5页 Last page